The North America Precision Diagnostics & Medicine Market is a rapidly expanding sector driven by advanced healthcare technologies and an increasing focus on personalized medicine approaches. The market size was valued at USD 27,970 Million in 2025 and is expected to reach USD 92,600 Million by 2035, growing at a CAGR of 11.6% from 2024 to 2035. Robust R&D investment, regulatory support, and a thriving ecosystem of biotechnology and diagnostic companies underpin growth in the U.S. and Canada.
The economic impact of tariffs on "North America Precision Diagnostics & Medicine Market".
Market Growth Drivers
Advancement in Genomic Technologies: Technological innovations in next-generation sequencing (NGS) and genetic testing are key drivers accelerating the precision diagnostics & medicine market in North America. Companies such as Illumina, Inc. are investing in simplifying and scaling genomic sequencing solutions, making them more accessible and cost-effective for clinical use. In late 2023, Illumina launched the NovaSeq X series, which significantly enhances sequencing speed and output, thereby enabling wider adoption in oncology, rare disease diagnosis, and population genomics projects. These advancements reduce turnaround times and improve diagnostic accuracy, fostering wider precision medicine integration.
Rising Prevalence of Chronic Diseases & Cancer: The growing burden of chronic diseases—especially cancer, cardiovascular, and rare genetic disorders—necessitates precise, targeted medical solutions. According to Roche, which is a major player in the sector, the demand for companion diagnostics and personalized therapeutics is rising as clinicians strive for optimized treatment plans. Roche’s collaboration with Bristol Myers Squibb in early 2024 for the co-development of companion diagnostics for oncology treatments showcases the vital role of partnerships in accelerating personalized patient care, improving survival outcomes, and fueling market expansion.
Market Trends
Integration of Artificial Intelligence in Diagnostic Platforms: The incorporation of AI and machine learning in diagnostics is a defining trend shaping the North American precision medicine landscape. PathAI, a U.S.-based company, recently partnered with Labcorp to deploy AI-powered pathology solutions to improve cancer detection rates and diagnostic accuracy. These systems scan and interpret complex tissue samples rapidly, streamlining workflows and enabling earlier interventions. The trend toward digital pathology and AI-driven analyses is anticipated to enhance efficiency and improve patient prognoses on a large scale.
Growth in Liquid Biopsy Adoption: The non-invasive nature of liquid biopsies is driving their increased application in early cancer detection and disease monitoring. Guardant Health announced in March 2024 their expanded collaboration with Pfizer to utilize Guardant360, a liquid biopsy platform, for advanced cancer screening and therapy monitoring. Liquid biopsies offer fast, real-time insights and eliminate the need for surgical tissue sampling, thus accelerating the shift toward decentralized, patient-centered diagnostic paradigms across the U.S. and Canada.
Market Opportunity
Expansion into Underserved Rural & Remote Areas: Precision diagnostics companies, like Quest Diagnostics, are increasing outreach to rural and remote communities in Canada and the U.S. Leveraging telemedicine and mobile health platforms, they provide genetic testing and personalized health solutions to previously underdiagnosed populations, thus opening new revenue streams.
Collaborative Development with Pharmaceutical Companies: Partnerships between diagnostic firms and pharmaceutical companies create opportunities for co-developing companion diagnostics for targeted therapies. Thermo Fisher Scientific’s joint ventures with multiple pharma companies in 2023 are prime examples, enabling precision therapeutics and broadening the use of personalized medication regimens.
North America Precision Diagnostics & Medicine Market Revenue (2020-2035)
The chart depicts a strong growth trajectory for the North America Precision Diagnostics & Medicine Market from 2020 to 2035. Total market revenue surged from USD 8,700 Million in 2020 to USD 27,970 Million in 2025, reflecting rapid adoption of advanced diagnostics and precision therapies. With the proliferation of AI-powered platforms and liquid biopsy technologies, the market is forecast to reach USD 92,600 Million by 2035. Key growth inflection points correspond to regulatory approvals and new product launches, particularly after 2025, as next-gen solutions become mainstream. The compound annual growth rate (CAGR) of 11.6% suggests sustained investment and innovation throughout the forecast period. Overall, the chart underscores North America’s global leadership in precision medicine driven by rising healthcare spending, partnerships, and R&D advances.
North America Precision Diagnostics & Medicine Market Share by Region, 2025
In 2025, the U.S. dominates the North America Precision Diagnostics & Medicine Market, accounting for approximately 75% share owing to its advanced healthcare infrastructure, strong R&D pipeline, and leading biotech industry. Canada follows with 16%, benefiting from improvements in precision oncology and government initiatives supporting genomics. Mexico represents a growing market, holding 6% share, largely driven by rising healthcare expenditure and wider adoption of genetic diagnostics in urban centers. The rest of North America, including Caribbean nations, collectively accounts for 3%. The pie chart highlights the significant market concentration in the U.S. with growing contribution from other North American countries as access and regulatory frameworks evolve.
Recent Developments in North America Precision Diagnostics & Medicine Market
In February 2024, Illumina, Inc. announced the launch of its TruSight Oncology Comprehensive (EU) assay in the U.S., a pan-cancer test delivering extensive genomic profiling across more than 500 genes. The move aims to accelerate adoption among leading cancer centers and expand precision treatment selection, amplifying the company’s market presence.
Guardant Health revealed in March 2024 its expanded strategic collaboration with Pfizer to advance the use of the Guardant360 liquid biopsy platform for oncology research and clinical trials in North America. This partnership strengthens the integration of non-invasive, real-time screening in drug development, improving outcomes for patients with advanced cancer.
In April 2024, Thermo Fisher Scientific and AstraZeneca announced their co-development of advanced companion diagnostics for lung cancer therapies. The partnership leverages Thermo Fisher’s molecular diagnostics expertise to identify eligible patients for AstraZeneca’s targeted treatments, promising quicker access to life-saving therapies and further embedding precision medicine into mainstream cancer care.
Press Releases